Geron Corporation (GERN) Receives "Hold" Rating from Needham & Company LLC

The company's quarterly EPS surprised Wall Street by as much as -21% to the downside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.

Geron Corporation shares had a trading volume of 2,889K by the end of trading on Monday. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.40 million. During the same period in the previous year, the company posted ($0.02) earnings per share. analysts predict that Geron Corporation will post -0.17 EPS for the current year. 756,300 shares of the company traded hands, compared to its average volume of 1,409,538. Geron Corporation's revenue for the quarter was down 96.8% on a year-over-year basis. Among holders that decreased their positions, 14 sold out of the stock Geron Corporation.

What the Technicals Say About The Interpublic Group of Companies, Inc. (IPG)
Credit Suisse Group set a $26.00 price objective on Interpublic Group of Companies, Inc. (The) by 29.9% in the first quarter. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover LLNW having a buy-equivalent rating.

GERN has been the topic of a number of other reports. If the published price targets set by Fred's, Inc. analysts have any power to influence the stock's share price, the highest price target set for FRED is $12. The company maintains price to book ratio of 3.03 vs.an industry average at 19.02. BidaskClub downgraded shares of Geron Corporation from a "hold" rating to a "sell" rating in a research report on Saturday, August 5th. The stock now has a consensus rating of "Hold" and a consensus price target of $3.75.

TRADEMARK VIOLATION WARNING: This article was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and worldwide copyright and trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/13/geron-corporations-gern-hold-rating-reaffirmed-at-stifel-nicolaus.html. Parametric Portfolio Associates LLC raised its stake in shares of Geron Corporation by 59.4% in the second quarter. American International Group Inc expanded its holdings by buying 7,454 shares an increase of 8.1%. BlackRock Investment Management LLC boosted its stake in Geron Corp.by 4.0% in the second quarter.

Dallas prosecutor who accused Uber driver of kidnapping fired from her job
So do you want to take me home or do you want to stay here? "But you don't treat people that way". "I just want an apology". She said this was the only job I can get because I'm so stupid. "There's just a little bit more to it and I was wrong".

A few notable investment firms have updated their holdings. Among active positions in the latest quarter, 48 holders increased their positions by a total of 3.05 million shares, 44 holders decreased the positions by a total of 985539 shares, and 35 holders held their positions. Janney Montgomery Scott LLC now owns 132,200 shares of the biopharmaceutical company's stock valued at $354,000 after buying an additional 65,100 shares in the last quarter. The value of the total investment in Geron Corporation went from $730,000 to $524,000 a change of $206,000 quarter to quarter. Parametric Portfolio Associates LLC now owns 47,976 shares of the biopharmaceutical company's stock worth $133,000 after buying an additional 17,877 shares during the period.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen).

Boycotting Arab nations don't want to negotiate: Qatari Emir
The emir of Qatar Sheikh Tamim bin Hamad al-Thani said Tuesday that Qatar won't obey the demands by the Saudi-led countries. Qatar, which is scheduled to host the 2022 World Cup, insists that it is economically strong enough to survive the crisis.

Últimas notícias